Table 5.

Cost-effectiveness results of multiple PrEP scenarios

PrEP scenario	Coverage (%)			Adherence			Eligibility	ICER ($/QALY)	ICER ($/QALY)	ICER ($/QALY)

	All	Black	White	All	Black	White		Black	White	All

1 (base-case)	40	40	40	20.9%, 24.4%, 13.1%, 41.6%^a			Aged 16–18 and AI experienced	33,064	427,788	116,971
2	30	19	41					29,275	539,573	188,016
3	40	26	54					33,469	558,259	196,249
4	50	32	68					31,525	576,626	194,419
5	30	19	41	20.9%, 24.4%, 13.1%, 41.6%	30.9%, 18.7%, 18.7%, 31.7%	10.9%, 18.8%, 18.8%, 51.5%		33,616	473,581	184,166
6	40	26	54	20.9%, 24.4%, 13.1%, 41.6%	30.9%, 18.7%, 18.7%, 31.7%	10.9%, 18.8%, 18.8%, 51.5%		41,637	466,783	192,680
7	50	32	68					45,274	512,706	204,084
8	40	40	40	20.9%, 24.4%, 13.1%, 41.6%			Aged 16–18 and 10+ CAI in last 6 mo	17,008	372,306	91,782
9	30	19	41	20.9%, 24.4%, 13.1%, 41.6%			Aged 16–18 and 10+ CAI in last 6 mo	10,461	456,654	148,477
10	40	26	54					15,411	485,126	159,256
11	50	32	68					14,488	513,673	160,067
12	30	19	41	20.9%, 24.4%, 13.1%, 41.6%	30.9%, 18.7%, 18.7%, 31.7%	10.9%, 18.8%, 18.8%, 51.5%		31,550	403,256	168,700
13	40	26	54	20.9%, 24.4%, 13.1%, 41.6%	30.9%, 18.7%, 18.7%, 31.7%	10.9%, 18.8%, 18.8%, 51.5%		22,640	427,013	160,793
14	50	32	68		31,871	452,017	176,344

AI = anal intercourse; CAI = condomless anal intercourse; ICER = incremental cost-effectiveness ratio; PrEP = pre-exposure prophylaxis; QALY = quality-adjusted life years.

The cohort adherence included 20.9%, 24.4%, 13.1%, and 41.6% of PrEP users with no measurable adherence, low (<2 pills/wk), medium (2–3 pills/wk), and high adherence (>4 pills/wk), respectively.